Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
| Data | Nome del titolare | Azioni transazionate | Intervallo di valore ($) | Tipo di transazione | Intervallo di prezzo ($) | Azioni a fine dichiarazione | % di variazione |
|---|---|---|---|---|---|---|---|
| 2026-05-08 | Mr. Gregory Thomas LucierIndependent Director | 10,00k | 83,20k | Acquisto | 8,32 | 60,00k | 20,00% |
| 2026-05-01 | Mr. Simon P. DingemansIndependent Director | 25,00k | 203,50k | Acquisto | 8,14 | 31,23k | 401,61% |
| 2026-03-10 | Mr. Sanjeev Kishen MehraIndependent Director | 125,00k | 1,00M | Acquisto | 8,01 | 475,00k | 35,71% |
| 2026-02-23 | Mr. R. Brent JonesInsider | -2,81k | 24,94k | Sale to Issuer | 8,89 | 39,95k | -6,56% |
| 2026-02-23 | Mr. Claudius O. SokenuExec. VP, Corporate Secretary and Chief Legal & Compliance Officer | -2,38k | 21,12k | Sale to Issuer | 8,89 | 16,89k | -12,33% |
| 2026-02-23 | Mr. Steven W. EckSenior VP, Interim CFO, Corporate Controller & CAO | -2,47k | 22,05k | Sale to Issuer | 8,89 - 9,11 | 99,33k | -2,43% |
| 2026-02-23 | Mr. Benoit GourdierExec. VP of Bioscience Production | -3,03k | 26,93k | Sale to Issuer | 8,89 | 24,86k | -10,86% |
| 2026-02-23 | Ms. Brittany HankamerExec. VP & Chief HR Officer | -1,68k | 15,04k | Sale to Issuer | 8,89 - 9,11 | 249,05k | -0,67% |
| 2026-02-19 | Mr. Gregory Thomas LucierIndependent Director | 50,00k | 458,00k | Acquisto | 9,16 | 50,00k | - |
| 2026-02-20 | Mr. Steven W. EckSenior VP, Interim CFO, Corporate Controller & CAO | -2,13k | 19,19k | Sale to Issuer | 9,03 | 101,80k | -2,04% |
| 2026-02-20 | Ms. Brittany HankamerExec. VP & Chief HR Officer | -1,45k | 13,12k | Sale to Issuer | 9,03 | 250,73k | -0,58% |
| 2026-02-20 | Mr. Claudius O. SokenuExec. VP, Corporate Secretary and Chief Legal & Compliance Officer | -2,92k | 26,36k | Sale to Issuer | 9,03 | 19,27k | -13,16% |
| 2026-02-20 | Mr. Corey D. WalkerPresident of Laboratory Solutions | -4,96k | 44,82k | Sale to Issuer | 9,03 | 16,02k | -23,65% |
| 2026-02-20 | Mr. R. Brent JonesInsider | -9,51k | 85,84k | Sale to Issuer | 9,03 | 34,20k | -21,75% |
| 2026-02-20 | Mr. Benoit GourdierExec. VP of Bioscience Production | -4,16k | 37,56k | Sale to Issuer | 9,03 | 19,33k | -17,71% |
| 2026-02-12 | Mr. Gregory L. SummeIndependent Chairman of the Board | 100,00k | 940,00k | Acquisto | 9,40 | 441,01k | 29,32% |
| 2025-12-05 | Mr. Sanjeev Kishen MehraIndependent Director | 350,00k | 3,88M | Acquisto | 11,09 | 350,00k | - |
| 2025-11-17 | Mr. Emmanuel LignerPresident, CEO & Director | 87,50k | 993,13k | Acquisto | 11,35 | 87,50k | - |
| 2025-10-30 | Mr. Gregory L. SummeIndependent Chairman of the Board | 100,00k | 1,13M | Acquisto | 11,25 | 341,01k | 41,49% |
| 2025-10-02 | Mr. Benoit GourdierExec. VP of Bioscience Production | -1,26k | 17,41k | Sale to Issuer | 13,77 | 11,58k | -9,84% |
| 2025-08-21 | Mr. Gregory L. SummeIndependent Chairman of the Board | 100,00k | 1,26M | Acquisto | 12,56 | 241,01k | 70,92% |
| 2025-08-14 | Ms. Brittany HankamerExec. VP & Chief HR Officer | -181,00 | 2,35k | Sale to Issuer | 12,98 | 171,56k | -0,11% |
| 2025-08-05 | Mr. Steven W. EckSenior VP, Interim CFO, Corporate Controller & CAO | -3,48k | 39,59k | Vendita | 11,39 | 55,07k | -5,94% |
| 2025-07-31 | Mr. Steven W. EckSenior VP, Interim CFO, Corporate Controller & CAO | -1,39k | 18,61k | Sale to Issuer | 13,44 | 58,54k | -2,31% |
| 2025-07-24 | Mr. Claudius O. SokenuExec. VP, Corporate Secretary and Chief Legal & Compliance Officer | -3,12k | 43,75k | Sale to Issuer | 14,01 | 15,04k | -17,19% |
| 2025-06-21 | Mr. Corey D. WalkerPresident of Laboratory Solutions | -2,73k | 37,05k | Sale to Issuer | 13,57 | 6,69k | -28,99% |
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Registrati con e-mail
Hai già un account? Accedi
Non hai un account? Registrati
Registrandomi, confermo di aver letto, capito, e accetto i termini e condizioni ADVFN e che sono un investitore privato.
Caratteristiche principali
Premium
